Banca de DEFESA: BRUNA SAMPAIO MARTINS LAND MANIER

Uma banca de DEFESA de DOUTORADO foi cadastrada pelo programa.
STUDENT : BRUNA SAMPAIO MARTINS LAND MANIER
DATE: 14/02/2025
TIME: 13:00
LOCAL: Defesa em formato híbrido
TITLE:

MYELOPROTECTIVE EFFECT OF THYMOMODULIN IN DOGS WITH CANINE TRANSMISSIBLE VENEREAL TUMOR SUBMITTED TO ANTINEOPLASTIC CHEMOTHERAPY WITH VINCRISTINE SULFATE

KEY WORDS:

Leukopenia, myelosuppression, neoplasms, chemotherapy

PAGES: 70
BIG AREA: Ciências Agrárias
AREA: Medicina Veterinária
SUBÁREA: Clínica e Cirurgia Animal
SPECIALTY: Clínica Veterinária
SUMMARY:

The number of dogs diagnosed with neoplasia has increased every year, either due to the increase in the longevity of animals resulting from more effective control of infectious and parasitic diseases that were previously responsible for the premature death of animals, or due to the improvement in the diagnosis of neoplasia. Dogs and cats are considered members of the family, and when diagnosed with cancer, owners have sought more effective treatments, with fewer side effects, that aim to cure or alleviate the consequences of this disease in animals, increasing not only survival, but also improving the quality of life of animals. Currently, several protocols are available for the treatment of neoplasia, with chemotherapy being one of the most widely used, either as a single therapy or in combination with surgery or radiotherapy. Vincristine sulfate is one of the main drugs used in chemotherapy for humans and companion animals, with the caveat that it is a potent myelosuppressive agent. Among the tumors whose chemotherapy protocol is based on the use of vincristine is canine transmissible venereal tumor (TVTC), one of the most frequently diagnosed neoplasms in routine oncology at the Veterinary Hospital of the Federal Rural University of Rio de Janeiro (UFRRJ). For the treatment of TVTC, a weekly protocol with vincristine sulfate is instituted, with an average of 4 to 6 sessions until complete remission of the neoplasm. The animals must be monitored weekly with blood tests to identify possible adverse effects, since intense leukopenia increases the chances of death as a result of sepsis. In the most severe cases of myelosuppression, veterinary medicine has empirically used thymomodulin. Although there is no scientific proof, the preliminary results in animals treated at the UFRRJ oncology service are encouraging in hematological recovery. The objectives of the project are: (i) to evaluate the bone marrow response of animals to the use of thymomodulin in cases where there are episodes of myelosuppression induced by antineoplastic chemotherapy with vincristine sulfate; (ii) to evaluate the prophylactic use of thymomodulin in dogs undergoing antineoplastic chemotherapy with vincristine sulfate. Thirty dogs diagnosed with CTVT will be used and divided into three experimental groups. Group I – 10 dogs treated with vincristine sulfate at a dose of 0.75 mg/m2 administered intravenously every seven days (control group); Group II – 10 dogs treated with vincristine sulfate at a dose of 0.75 mg/m2 administered intravenously every seven days, associated with thymomodulin at a dose of 2 mL every 12 hours, throughout the chemotherapy protocol; Group III – 10 dogs treated with vincristine sulfate at a dose of 0.75 mg/m2 administered intravenously every seven days, combined with thymomodulin at a dose of 2 mL every 12 hours for seven days in animals with episodes of myelosuppression. The animals will undergo treatment until the neoplasia identified by cytological examination is cured. It is expected to prove that thymomodulin helps in the treatment and prevention of myelosuppression caused by vincristine.

COMMITTEE MEMBERS:
Presidente - 4563410 - JULIO ISRAEL FERNANDES
Interno - 1151827 - BRUNO RICARDO SOARES ALBERIGI DA SILVA
Interno - 1120060 - ALEXANDRE JOSE RODRIGUES BENDAS
Interna - 2572430 - CRISTIANE DIVAN BALDANI
Externa à Instituição - RENATA SANTIAGO ALBERTO COSTA - UESC-BA
Externo à Instituição - FLAVYA MENDES DE ALMEIDA - UFF
Externo à Instituição - ARY ELIAS ABOUD DUTRA - UVA
Externo à Instituição - CAROLINA FRANCHI JOÃO - UFU